Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma

Hiroshi Saeki, Masaru Morita, Yuichiro Nakashima, Hideto Sonoda, Kenkichi Hashimoto, Akinori Egashira, O. K.I. Eiji, Takefumi Ohga, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The clinical significance of neoadjuvant chemoradiotherapy (NACRT) for potentially resectable esophageal squamous cell carcinoma (ESCC) is unclear. Patients and Methods: Patients with clinical stage II-III ESCC were classified into an NACRT group (n=76) and surgery alone group (n=92). The prognosis and the incidence of postoperative complications were retrospectively investigated. The pathological response to NACRT and patient prognosis were also analyzed. Results: The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group (p=0.4831). The 5-year survival rates of patients in whom NACRT was markedly effective was clearly better than that of the other patients (ineffective/slightly effective: 36.9%, moderately effective: 53.8%, markedly effective: 100%). The incidence of postoperative complications was 31.5% in the surgery alone group and 40.8% in the NACRT group (p=0.2121). Conclusion: A pathological complete response to NACRT is critical for improving the survival of patients with clinical stageII-III ESCC.

Original languageEnglish
Pages (from-to)3073-3077
Number of pages5
JournalAnticancer research
Volume31
Issue number9
Publication statusPublished - Sep 1 2011

Fingerprint

Chemoradiotherapy
Survival Rate
Incidence
Esophageal Squamous Cell Carcinoma
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Saeki, H., Morita, M., Nakashima, Y., Sonoda, H., Hashimoto, K., Egashira, A., ... Maehara, Y. (2011). Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. Anticancer research, 31(9), 3073-3077.

Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. / Saeki, Hiroshi; Morita, Masaru; Nakashima, Yuichiro; Sonoda, Hideto; Hashimoto, Kenkichi; Egashira, Akinori; Eiji, O. K.I.; Ohga, Takefumi; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Anticancer research, Vol. 31, No. 9, 01.09.2011, p. 3073-3077.

Research output: Contribution to journalArticle

Saeki, H, Morita, M, Nakashima, Y, Sonoda, H, Hashimoto, K, Egashira, A, Eiji, OKI, Ohga, T, Kakeji, Y & Maehara, Y 2011, 'Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma', Anticancer research, vol. 31, no. 9, pp. 3073-3077.
Saeki H, Morita M, Nakashima Y, Sonoda H, Hashimoto K, Egashira A et al. Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. Anticancer research. 2011 Sep 1;31(9):3073-3077.
Saeki, Hiroshi ; Morita, Masaru ; Nakashima, Yuichiro ; Sonoda, Hideto ; Hashimoto, Kenkichi ; Egashira, Akinori ; Eiji, O. K.I. ; Ohga, Takefumi ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma. In: Anticancer research. 2011 ; Vol. 31, No. 9. pp. 3073-3077.
@article{d2971001ac4a4b259687dedc7e3b4c96,
title = "Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma",
abstract = "Background: The clinical significance of neoadjuvant chemoradiotherapy (NACRT) for potentially resectable esophageal squamous cell carcinoma (ESCC) is unclear. Patients and Methods: Patients with clinical stage II-III ESCC were classified into an NACRT group (n=76) and surgery alone group (n=92). The prognosis and the incidence of postoperative complications were retrospectively investigated. The pathological response to NACRT and patient prognosis were also analyzed. Results: The 5-year survival rate was 47.7{\%} in the surgery alone group and 56.5{\%} in the NACRT group (p=0.4831). The 5-year survival rates of patients in whom NACRT was markedly effective was clearly better than that of the other patients (ineffective/slightly effective: 36.9{\%}, moderately effective: 53.8{\%}, markedly effective: 100{\%}). The incidence of postoperative complications was 31.5{\%} in the surgery alone group and 40.8{\%} in the NACRT group (p=0.2121). Conclusion: A pathological complete response to NACRT is critical for improving the survival of patients with clinical stageII-III ESCC.",
author = "Hiroshi Saeki and Masaru Morita and Yuichiro Nakashima and Hideto Sonoda and Kenkichi Hashimoto and Akinori Egashira and Eiji, {O. K.I.} and Takefumi Ohga and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2011",
month = "9",
day = "1",
language = "English",
volume = "31",
pages = "3073--3077",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Neoadjuvant chemoradiotherapy for clinical stage II-III esophageal squamous cell carcinoma

AU - Saeki, Hiroshi

AU - Morita, Masaru

AU - Nakashima, Yuichiro

AU - Sonoda, Hideto

AU - Hashimoto, Kenkichi

AU - Egashira, Akinori

AU - Eiji, O. K.I.

AU - Ohga, Takefumi

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: The clinical significance of neoadjuvant chemoradiotherapy (NACRT) for potentially resectable esophageal squamous cell carcinoma (ESCC) is unclear. Patients and Methods: Patients with clinical stage II-III ESCC were classified into an NACRT group (n=76) and surgery alone group (n=92). The prognosis and the incidence of postoperative complications were retrospectively investigated. The pathological response to NACRT and patient prognosis were also analyzed. Results: The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group (p=0.4831). The 5-year survival rates of patients in whom NACRT was markedly effective was clearly better than that of the other patients (ineffective/slightly effective: 36.9%, moderately effective: 53.8%, markedly effective: 100%). The incidence of postoperative complications was 31.5% in the surgery alone group and 40.8% in the NACRT group (p=0.2121). Conclusion: A pathological complete response to NACRT is critical for improving the survival of patients with clinical stageII-III ESCC.

AB - Background: The clinical significance of neoadjuvant chemoradiotherapy (NACRT) for potentially resectable esophageal squamous cell carcinoma (ESCC) is unclear. Patients and Methods: Patients with clinical stage II-III ESCC were classified into an NACRT group (n=76) and surgery alone group (n=92). The prognosis and the incidence of postoperative complications were retrospectively investigated. The pathological response to NACRT and patient prognosis were also analyzed. Results: The 5-year survival rate was 47.7% in the surgery alone group and 56.5% in the NACRT group (p=0.4831). The 5-year survival rates of patients in whom NACRT was markedly effective was clearly better than that of the other patients (ineffective/slightly effective: 36.9%, moderately effective: 53.8%, markedly effective: 100%). The incidence of postoperative complications was 31.5% in the surgery alone group and 40.8% in the NACRT group (p=0.2121). Conclusion: A pathological complete response to NACRT is critical for improving the survival of patients with clinical stageII-III ESCC.

UR - http://www.scopus.com/inward/record.url?scp=80051638162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051638162&partnerID=8YFLogxK

M3 - Article

C2 - 21868562

AN - SCOPUS:80051638162

VL - 31

SP - 3073

EP - 3077

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -